Albumin–protamine–oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect
- 3 February 2005
- journal article
- research article
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 59 (3) , 431-438
- https://doi.org/10.1016/j.ejpb.2004.07.014
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Albumin–protamine–oligonucleotide nanoparticles as a new antisense delivery system. Part 1: Physicochemical characterizationEuropean Journal of Pharmaceutics and Biopharmaceutics, 2005
- Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivationJournal of Controlled Release, 2004
- Antisense Oligonucleotides: Promise and RealityAnnual Review of Pharmacology and Toxicology, 2001
- Cellular delivery of antisense oligonucleotidesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2000
- Effects of NMDA-R1 antisense oligodeoxynucleotide administration: behavioral and radioligand binding studiesBrain Research, 1997
- Phosphorothioate antisense oligodeoxynucleotides: questions of specificityTrends in Biotechnology, 1996
- Cloning, Functional Coexpression, and Pharmacological Characterisation of Human cDNAs Encoding NMDA Receptor NR1 and NR2A SubunitsJournal of Neurochemistry, 1994
- Reduction of erbB2 Gene-Product in Mamma Carcinoma Cell Lines by erbB2 mRNA-Specific and Tyrosine Kinase Consensus Phosphorothioate Antisense OligonucleotidesBiochemical and Biophysical Research Communications, 1994
- Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctionsNature, 1993
- The Use of Potassium Gluconate in HypopotassemiaScience, 1951